Skip Navigation

European Journal of Heart Failure 2002 4(3):381-388; doi:10.1016/S1388-9842(02)00040-5
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coletta, A.
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coletta, A.
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 European Society of Cardiology

Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL

Alison Coletta, Simon Thackray, Nikolay Nikitin and John G.F. Cleland*

Department of Academic Cardiology Castle Hill Hospital, Cottingham, Kingston upon Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44-1482-624084; fax: +44-1482-624085. E-mail address: g.m.porter{at}hull.ac.uk


  Abstract

This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the American College of Cardiology 51st Annual Scientific Session held in Atlanta on 17–20 March 2002. Reports of the following clinical studies are included: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL.

Key Words: LIFE • DANAMI 2 • MADIT-2 • MIRACLE-ICD • OVERTURE • OCTAVE • ENABLE 1 & 2 • CHRISTMAS • AFFIRM • RACE • WIZARD • AZACS • REMATCH • BNP trial • HARDBALL

Received March 28, 2002; Revised April 8, 2002; Accepted April 9, 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, A. T. Abdellah, D. Cullington, A. L. Clark, and A. S. Rigby
Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy
Eur J Heart Fail, January 1, 2008; 10(1): 102 - 108.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. J. V. McMurray, J. R. Teerlink, G. Cotter, R. C. Bourge, J. G. F. Cleland, G. Jondeau, H. Krum, M. Metra, C. M. O'Connor, J. D. Parker, et al.
Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials
JAMA, November 7, 2007; 298(17): 2009 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S J Leslie, J C S Spratt, S P McKee, F E Strachan, D E Newby, D B Northridge, M A Denvir, and D J Webb
Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure
Heart, July 1, 2005; 91(7): 914 - 919.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M P Frenneaux
Autonomic changes in patients with heart failure and in post-myocardial infarction patients
Heart, November 1, 2004; 90(11): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J. G.F. Cleland and K. Goode
Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?
Eur J Heart Fail, March 15, 2004; 6(3): 253 - 255.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. M. Richards
Vasopeptidase inhibitors for heart failure: where do we go from here?
Eur J Heart Fail, August 1, 2003; 5(4): 411 - 413.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. W. Troughton, C. M. Frampton, T. G. Yandle, E. A. Espiner, G. Nicholls, and M. Richards
Plasma Amino-Terminal B-Type Natriuretic Peptide Measured by Elecsys 2010 Assay in a Trial of Hormone-guided Treatment for Heart Failure
Clin. Chem., July 1, 2003; 49(7): 1212 - 1215.
[Full Text] [PDF]

Home page
 Eur J Heart FailHome page
J.G.F. Cleland, N. Freemantle, S.G. Ball, R.S. Bonser, P. Camici, S. Chattopadhyay, D. Dutka, J. Eastaugh, J. Hampton, S. Large, et al.
The heart failure revascularisation trial (HEART): rationale, design and methodology
Eur J Heart Fail, June 1, 2003; 5(3): 295 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. G.F. Cleland, J. Ghosh, N. K. Khan, S. Ghio, L. Tavazzi, and G. Kaye
Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony?
Eur. Heart J., March 1, 2003; 24(5): 384 - 390.
[Full Text] [PDF]

Home page
 StrokeHome page
M. Prager, Z. Turel, W. S. Speidl, G. Zorn, C. Kaun, A. Niessner, G. Heinze, I. Huk, G. Maurer, K. Huber, et al.
Chlamydia pneumoniae in Carotid Artery Atherosclerosis: A Comparison of Its Presence in Atherosclerotic Plaque, Healthy Vessels, and Circulating Leukocytes From the Same Individuals
Stroke, December 1, 2002; 33(12): 2756 - 2761.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A.P. Coletta, A.A. Louis, A.L. Clark, N. Nikitin, and J.G.F. Cleland
Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II
Eur J Heart Fail, October 1, 2002; 4(5): 661 - 666.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.